ArriVent BioPharma, Inc. Common Stock
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
3.00 |
5.50 |
4.90 |
53.95 |
179.91 |
316.17 |
| Przychód Δ r/r |
0.00% |
83.33% |
-10.91% |
1000.97% |
233.49% |
75.74% |
| Przychód (min) |
3.00 |
5.50 |
4.90 |
53.95 |
179.91 |
316.17 |
| Przychód (max) |
3.00 |
5.50 |
4.90 |
53.95 |
179.91 |
316.17 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-82.54 |
-114.53 |
-134.38 |
-58.61 |
4.72 |
109.83 |
| Zysk netto % |
-2751.22% |
-2082.37% |
-2742.47% |
-108.63% |
2.62% |
34.74% |
| EPS (średnia) |
-2.58 |
-3.64 |
-3.10 |
-1.89 |
0.15 |
3.49 |
| Liczba analityków (Przychody) |
2 |
4 |
7 |
6 |
2 |
5 |
| Liczba analityków (EPS) |
4 |
5 |
7 |
5 |
2 |
1 |
| symbol |
AVBP |
AVBP |
AVBP |
AVBP |
AVBP |
AVBP |